

	Biogen BLIB CinMIC Latisha Large Biotechnology Count: 4	Gilead Sciences GILD CinMIC Kate Large Biotechnology Count: 9	Novo-Nordisk NVO CinMIC Ian Large Biotechnology Count: 7			Industry averages:
--	---	---	--	--	--	--------------------

► Growth Comparisons

Hist. Sales Growth Rate - 10 YR (%)	15.5%	26.1%	10.8%			
Hist. Sales Growth Rate - 5 YR (%)	23.1%	44.2%	7.0%			
Estimated Sales Growth Rate (%)	8.4%	4.0%	5.4%			
Hist. Earnings/Share Growth Rate - 10 YR (%)	34.5%	32.6%	21.8%			
Hist. Earnings/Share Growth Rate - 5 YR (%)	34.9%	70.0%	15.7%			
Estimated Earnings Per Share Growth Rate (%)	9.5%	4.0%	8.4%			
Earnings Stability (R-squared) - 10 YR	.92	.74	.98			
Earnings Stability (R-squared) - 5 YR	.97	.80	.97			

► Management Comparisons

% Pretax Profit on Sales (Last 5 Year Average)	37.7%	48.9%	37.2%			
% Earned on Equity (Last 5 Year Average)	24.3%	54.9%	60.3%			
% Debt to Capital	16.2%	47.2%	1.6%			

► Valuation Comparisons

Present Price	313.03	79.12	41.59			
Present Price / Estimated Total EPS	2.8	1.2	3.1			
Price Range (Last 5 Years)	64.28 - 480.18	17.23 - 123.37	18.92 - 60.34			
Current High P/E	31.3	10.4	30.0			
Average High P/E	29.3	12.8	26.0			
Average P/E	24.1	10.7	22.3			
Average Low P/E	18.9	8.5	18.6			
Current Low P/E	16.6	7.2	20.7			
Current P/E	18.3	7.0	19.8			
Lower Buy Price Zone (25%)	223.02 - 312.76	69.00 - 91.45	37.30 - 48.45			
Middle Hold Price Zone (50%)	312.76 - 492.25	91.45 - 136.35	48.45 - 70.75			
Upper Sell Price Zone (25%)	492.25 - 581.99	136.35 - 158.80	70.75 - 81.90			
Present Price Indicator	Hold	Buy	Buy			
Upside/Downside Ratio	2.99 to 1	7.87 to 1	9.40 to 1			
Relative Value	75.4%	65.3%	88.6%			
P/E: Projected Growth Rate (PEG)	175.6%	167.6%	217.0%			

► Potential Return Comparisons

Present Yield	0.00%	1.63%	1.80%			
Avg. Percent Payout	0.00%	23.41%	34.70%			
Compound Annual Return - Forecast High P/E	13.2%	17.0%	15.9%			
Compound Annual Return - Forecast Avg P/E	10.7%	14.1%	12.6%			

► Other Comparisons

Sector	Healthcare	Healthcare	Healthcare			
Industry	Biotechnology	Biotechnology	Biotechnology			
Total Sales Last FY	10,763.8 (Large)	32,639.0 (Large)	16,051.0 (Large)			
Current Diluted Shares Outstanding (M)	219.4	1,355.0	0.0			
% Insider Ownership	0.9%	0.6%	—			
% Institutional Ownership	90.4%	79.0%	7.6%			
Price Date	Sep 30, 2016	Sep 30, 2016	Sep 30, 2016			
Last Reported Quarter	Jun 30, 2016	Jun 30, 2016	Jun 30, 2016			
Judgment Date	Oct 01, 2016	Oct 01, 2016	Oct 01, 2016			
ADR	N	N	Y			
Country	USA	USA	DNK			